WNT7B and glioblastoma: In a fatal disease like GBM where all phase III immunotherapy trials have failed (1, 3) and limited survival benefits noted with the current standard of care, we have identified the Wnt7b/β-catenin pathway as a potential biomarker of response to WNT974 and αPD1.